Home > In process > Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays. > print

001     285056
005     20260209153611.0
024 7 _ |a 10.1002/alz.71192
|2 doi
024 7 _ |a pmid:41657128
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2026-00180
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a van der Veere, Pieter J
|0 0000-0002-1671-6850
|b 0
245 _ _ |a Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays.
260 _ _ |a Hoboken, NJ
|c 2026
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770647723_24271
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys platform.We included 2413 MCI participants (998 [41%] amyloid-positive) from seven observational cohorts. Elecsys was used in 958 (40%) participants. The parameters of the previous ABIDE Cox model were re-estimated. Model discrimination and calibration were evaluated with leave-one-cohort-out cross-validation.During follow-up, 1034 (42%; 585 [58%] amyloid-positive) participants developed dementia. Discrimination was good with Harrell's C of 0.70 (95% confidence interval [CI]: 0.66-0.73). Calibration was good in the total population and amyloid-positive subgroup, with substantial predicted progression risks for all amyloid-positive participants.We refitted the ABIDE model, predicting MCI to dementia progression, with automated CSF measurements. The model was well calibrated in amyloid-positive patients and may support clinical discussions regarding ATTs.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a automated cerebrospinal fluid assays
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a dementia
|2 Other
650 _ 7 |a mild cognitive dementia
|2 Other
650 _ 7 |a prediction
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnosis
|2 MeSH
650 _ 2 |a Dementia: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Dementia: diagnosis
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
700 1 _ |a van Harten, Argonde C
|b 1
700 1 _ |a van Maurik, Ingrid S
|b 2
700 1 _ |a Teunissen, Charlotte E
|b 3
700 1 _ |a Barkhof, Frederik
|b 4
700 1 _ |a Vos, Stephanie J B
|b 5
700 1 _ |a Froelich, Lutz
|b 6
700 1 _ |a Kornhuber, Johannes
|b 7
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 8
|u dzne
700 1 _ |a Maier, Wolfgang
|0 P:(DE-2719)2000015
|b 9
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 10
|u dzne
700 1 _ |a Rüther, Eckart
|b 11
700 1 _ |a Frisoni, Giovanni B
|b 12
700 1 _ |a Spiru, Luiza
|b 13
700 1 _ |a Freund-Levi, Yvonne
|b 14
700 1 _ |a Wallin, Åsa K
|b 15
700 1 _ |a Hampel, Harald
|b 16
700 1 _ |a Tsolaki, Magda
|b 17
700 1 _ |a Kłoszewska, Iwona
|b 18
700 1 _ |a Mecocci, Patrizia
|b 19
700 1 _ |a Vellas, Bruno
|b 20
700 1 _ |a Lovestone, Simon
|b 21
700 1 _ |a Galluzzi, Samantha
|b 22
700 1 _ |a Herukka, Sanna-Kaisa
|b 23
700 1 _ |a Santana, Isabel
|b 24
700 1 _ |a Baldeiras, I.
|b 25
700 1 _ |a de Mendonca, Alexandre
|b 26
700 1 _ |a Silva, Dina
|b 27
700 1 _ |a Chetelat, Gael
|b 28
700 1 _ |a Poisnel, Géraldine
|b 29
700 1 _ |a Visser, Pieter Jelle
|b 30
700 1 _ |a Johnson, Sterling C
|b 31
700 1 _ |a Stormrud, Erik
|b 32
700 1 _ |a Hansson, Oskar
|b 33
700 1 _ |a Palmqvist, Sebastian
|b 34
700 1 _ |a Piñol-Ripoll, Gerard
|b 35
700 1 _ |a Initiative, Alzheimer's Disease Neuroimaging
|b 36
|e Collaboration Author
700 1 _ |a Berkhof, Johannes
|b 37
700 1 _ |a van der Flier, Wiesje M
|b 38
773 _ _ |a 10.1002/alz.71192
|g Vol. 22, no. 2, p. e71192
|0 PERI:(DE-600)2201940-6
|n 2
|p e71192
|t Alzheimer's and dementia
|v 22
|y 2026
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/285056/files/DZNE-2026-00180.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285056/files/DZNE-2026-00180.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000015
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811024
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2026
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-11-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-11-11
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 0
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 1
920 1 _ |0 I:(DE-2719)5000000
|k AG Peters
|l Biomarker-Assisted Early Detection of Dementias
|x 2
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)5000000
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21